Octagon Capital Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-750,000
| Closed | -$29.8M | – | 29 |
|
|
2026
Q1 | $29.8M | Hold |
750,000
| – | – | 3.3% | 11 |
|
|
2025
Q4 | $18.8M | Sell |
750,000
-80,000
| -10% | -$2.03M | 2.28% | 18 |
|
|
2025
Q3 | $20.1M | Sell |
830,000
-200,000
| -19% | -$3.55M | 3.05% | 13 |
|
|
2025
Q2 | $13.5M | Sell |
1,030,000
-395,000
| -28% | -$5M | 2.97% | 17 |
|
|
2025
Q1 | $20.5M | Sell |
1,425,000
-568,052
| -29% | -$9.3M | 3.97% | 6 |
|
|
2024
Q4 | $33.4M | Sell |
1,993,052
-19,000
| -0.9% | -$315K | 5.49% | 4 |
|
|
2024
Q3 | $32.2M | Sell |
2,012,052
-333,023
| -14% | -$4.08M | 5% | 6 |
|
|
2024
Q2 | $21.2M | Buy |
2,345,075
+284,975
| +14% | +$2.7M | 3.33% | 9 |
|
|
2024
Q1 | $23.3M | Hold |
2,060,100
| – | – | 2.79% | 8 |
|
|
2023
Q4 | $16.4M | Buy |
2,060,100
+1,584,500
| +333% | +$10.6M | 2.62% | 11 |
|
|
2023
Q3 | $3.08M | Buy |
475,600
+63,672
| +15% | +$436K | 0.47% | 32 |
|
|
2023
Q2 | $2.55M | Buy |
411,928
+15,928
| +4% | +$75.6K | 0.35% | 32 |
|
|
2023
Q1 | $1.52M | Buy |
+396,000
| New | +$1.45M | 0.22% | 34 |
|
Octagon Capital Advisors's CNTA Position: Q2 2026 in Review
Octagon Capital Advisors sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 750,000 shares — an estimated $29.8M sold.
Octagon Capital Advisors first reported a position in CNTA in Q1 2023 and held it in 13 quarters. The position peaked at $33.4M in Q4 2024. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- Octagon Capital Advisors reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Octagon Capital Advisors sold 750,000 Centessa Pharmaceuticals shares in Q2 2026, an estimated $29.8M.
- Octagon Capital Advisors first reported a position in Centessa Pharmaceuticals in Q1 2023 and held it in 13 quarters.
- Octagon Capital Advisors's Centessa Pharmaceuticals position peaked at $33.4M in Q4 2024.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on Octagon Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.